Vaso Corporation (OTCQX: VASO), a prominent player in human capital, information technology, and MedTech, has announced significant changes to its executive leadership team and Board of Directors, effective January 1, 2025. These strategic appointments are aimed at enhancing the company’s operational efficiency and supporting its growth objectives for the coming year.
Jane Moen has been appointed as the Chief Operating Officer (COO) of Vaso Corporation. Moen, who has been with the company since 2018 and served as a Director since 2020, will also maintain her position as President of VasoHealthcare, a subsidiary focused on healthcare sales services. Her dual role is expected to leverage her extensive experience in both operational and strategic capacities to drive the company’s initiatives forward.
Jonathan Newton has been elevated to Chief Financial Officer (CFO) from his previous position as Co-CFO. This promotion reflects Newton’s strong financial acumen and his contributions to Vaso’s fiscal strategy. Michael Beecher, who previously shared the CFO role with Newton, will transition into a financial and investor relations advisory position, allowing him to focus on strategic financial guidance.
In addition to these executive appointments, Edgar Rios has been elected Vice Chairman of Vaso’s Board of Directors. Rios brings a wealth of experience as he has served as an independent Director since 2011 and will continue his responsibilities as Chairman of the Audit Committee.
To further bolster its governance framework, Vaso Corporation has appointed Kimberly Decker from Barley Snyder LLP as its new corporate and securities outside counsel. This move is part of Vaso’s commitment to ensuring robust legal oversight as it navigates complex market dynamics.
Dr. Jun Ma, President and CEO of Vaso Corporation, expressed optimism regarding these leadership changes. He stated that they reflect the company’s commitment to its mission centered on human capital and its focus on nurturing dedicated leaders within the organization. As Vaso embarks on implementing its 2025 strategy during this critical phase in its corporate journey, Dr. Ma emphasized the importance of organic growth across its diversified portfolio.
“Our top priority in 2025 will be to continue growing organically across our diversified portfolio businesses,” Dr. Ma said. He highlighted the importance of collaboration with customers and partners while exploring new strategic opportunities. The leadership team’s collective experience is expected to play a crucial role in achieving these objectives.
Vaso Corporation operates through three core subsidiaries: VasoHealthcare, which provides professional sales services for GE HealthCare’s diagnostic imaging products; VasoTechnology, specializing in information technology and managed connectivity services; and VasoMedical, which designs proprietary medical devices and operates the ARCS cloud-based SaaS platform.
As Vaso Corporation positions itself for future growth amid evolving market conditions, these leadership appointments signal a proactive approach to enhancing operational capabilities and reinforcing its commitment to innovation in healthcare technology. The company’s strategic focus on leveraging internal talent while adapting to industry demands will be pivotal in navigating the complexities of the MedTech landscape in 2025 and beyond.
